Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6234 Formulation 1 · 1 trial · 1 indication
Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations
Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations
Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations
| Arm | Type | Description |
|---|---|---|
| Sequence ABCD | EXPERIMENTAL | Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment A in Period 1, Treatment B in Period 2, Treatment C in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) |
| Sequence BCAD | EXPERIMENTAL | Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment B in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) |
| Sequence CABD | EXPERIMENTAL | Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment C in Period 1, Treatment A in Period 2, Treatment B in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) |
| Name | Type | Description |
|---|---|---|
| AZD6234 Formulation 1 | DRUG | AZD6234 Formulation 1 will be administered as a single SC injection |
| AZD6234 Formulation 2 (low concentration) | DRUG | AZD6234 Formulation 2 (low concentration) will be administered as a single SC injection |
| AZD6234 Formulation 2 (high concentration) | DRUG | AZD6234 Formulation 2 (high concentration) will be administered as a single SC injection |
| AZD6234 Formulation 3 | DRUG | AZD6234 Formulation 3 will be administered as a single SC injection |
Inclusion Criteria: * Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive * BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg Exclusion Criteria: * History of any clinically important disease or disorder * History or presence of clinically significant cardiovasc...
AZD6234 Formulation 1 is a small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with an active trial assessing the relative bioavailability of different subcutaneous formulations of AZD6234. The drug is investigational and has not been approved for any use.
AZD6234 Formulation 1 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting a Phase 1 clinical trial to evaluate the drug's bioavailability in healthy participants.
AZD6234 Formulation 1 is in Phase 1 clinical development. It is an investigational drug being studied in a single active trial that is not yet recruiting participants. The trial is designed to assess the relative bioavailability of different subcutaneous formulations of AZD6234 in healthy participants.
AZD6234 Formulation 1 is being studied in one Phase 1 clinical trial with the identifier NCT07220954. The trial, titled 'A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234,' is active but not recruiting, with an enrollment of 19 participants in the United Kingdom.
AZD6234 Formulation 1 is a specific formulation of the drug AZD6234. The clinical trial NCT07220954 is designed to compare the relative bioavailability of different subcutaneous formulations of AZD6234, with Formulation 1 being one of the formulations under investigation.